Madagascar vs Tonga: Hepatitis B surface antigen (HBsAg) prevalence
Madagascar
0.6%
in 2024
Tonga
0.6%
in 2024
Madagascar rank
51st
Tonga rank
51st
Hepatitis B surface antigen (HBsAg) prevalence over time
- Madagascar
- Tonga
How they compare
Madagascar currently reports 0.6% against 0.6% in Tonga, a difference of 0.0%.
Across all 10 years both countries report, Tonga has been ahead every year.
Madagascar ranks 51st and Tonga ranks 51st of 194 countries.
Tonga has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Madagascar | Tonga | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.6% | 1.1% | 0.4% | Tonga |
| 2020s | 0.5% | 0.7% | 0.2% | Tonga |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hepatitis b surface antigen (hbsag) prevalence, Madagascar or Tonga?
- Madagascar, at 0.6% against 0.6% in Tonga as of 2024.
- What is the difference in hepatitis b surface antigen (hbsag) prevalence between Madagascar and Tonga?
- 0.0%, with Madagascar ahead.
- How many years of comparable data are there for Madagascar and Tonga?
- 10 years are reported by both, from 2015 to 2024.
- How do Madagascar and Tonga rank globally for hepatitis b surface antigen (hbsag) prevalence?
- Madagascar ranks 51st and Tonga ranks 51st of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Hepatitis B surface antigen (HBsAg) prevalence (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.